Roth Capital Partners resumed coverage of Syros Pharmaceuticals (NASDAQ:SYRS) with a “buy” rating and $17 price target. The stock was quoted at $8.49 in afternoon trading on July 12. Syros was co-founded by ARCH Venture...

Stifel upgraded Rhythm Pharmaceuticals (NASDAQ:RYTM) to “buy” from “hold” but maintained its price target at $34, saying the stock is at an attractive entry point ahead of near-term Phase 3 results. The stock closed at...

Maxim Group reduced price targets for five biotech stocks, citing data troughs, financing conditions and political factors, which may be further compounded by a lack of catalysts and increasing operating expenses...

Stifel resumed coverage of Genocea Biosciences (NASDAQ:GHCA) with a “buy” rating and $13 price target. The stock closed at $3.83 on July 5.

H.C. Wainwright initiated coverage of PolarityTE (NASDAQ:PTE) with a “buy” rating and price target of $8. The stock closed at $5.52 on July 5.

Janney Montgomery Scott initiated coverage of Abcam plc (LSE:ABC) with a “buy” rating and fair value estimate of £17. The stock closed at £14.72 on July 1.

Dawson James launched coverage of Adamis Pharmaceuticals (NASDAQ:ADMP) with a “buy” rating and $5 price target. The stock closed at $1.30 on July 1.

H.C. Wainwright initiated coverage of Principia Biopharma (NASDAQ:PRNB) with a “buy” rating and $55 price target. The stock closed at $37.61, up $4.42, on July 1.

Dawson James Securities initiated coverage of IsoRay (NYSE American:ISR) with a “buy” rating and $1 price target. The stock closed at 41 cents on July 1.

Roth Capital Partners launched coverage of Fortress Biotech (NASDAQ:FBIO), which acquires and develops biopharmaceutical assets, with a “buy” rating and price target of $4. The stock closed at $1.55 on July 1.

Roth Capital Partners launched coverage of Netherlands-based Merus NV (NASDAQ:MRUS) with a “buy” rating and $20 price target. The stock closed at $14.12 on June 27.

Maxim Group downgraded Atossa Genetics (NASDAQ:ATOS) to “hold” from “buy” and removed its previous price target of $9 after the company reported results from its Phase 2 study evaluating topical endoxifen in patients...

GMP Securities initiated coverage of Zenabis Global (TSX:ZENA) with a “buy” rating and price target of $3.25. The stock was quoted at $1.29 in afternoon trading on June 27.

SVB Leerink downgraded Aclaris Therapeutics (NASDAQ:ACRS) to “market perform” from “outperform” and slashed its price target to $4 from $13 after the failure of the company’s topical treatment for alopecia areata, an...

H.C. Wainwright initiated coverage of Rubius Therapeutics (NASDAQ:RUBY) with a “buy” rating and $40 price target. The stock closed at $14.60 on June 25.

Maxim Group launched coverage of Titan Pharmaceuticals (NASDAQ:TTNP) with a “buy” rating and price target of $4. The stock closed at $1.44 on June 25.

BTIG raised its price target for Conformis (NASDAQ:CFMS) to $4.50 from $3 after the company arranged $33-million in debt and equity financing from Innovatus Capital Partners and East West Bank. The stock closed at $3.84...

SVB Leerink reduced its price target for Aduro Biotech (NASDAQ:ADRO) to $5 from $8 based on recent ADU-S100 (MIW815) Phase1b dose escalation data presentation at ASCO and re-evaluation of development assumptions in the...

In a new industry report on the future of NASH (nonalcoholic steatohepatitis), Stifel launched coverage of six NASH companies, with three “buy” and three “hold” recommendations.

William Blair downgraded Acer Therapeutics (NASDAQ:ACER) to “market perform” from “outperform” after the company received a complete response letter from the FDA for its lead product, Edsivo (celiprolol).

H.C. Wainwright initiated coverage of Medivir (NASDAQ, Stockholm:MVIR) with a “buy” rating and price target of SEK 54. The stock closed at SEK 22.55 on June 24.